Scholarlink

Background <p>Guanylate binding protein 5 (GBP5) belongs to an interferon (IFN)-inducible subfamily of guanosine triphosphatases (GTPases). GBP5 has been shown to promote NLRP3 inflammasome assembly, thereby playing a key role in innate immunity and inflammation. However, the role of GBP5 in the development of various cancers and its potential as a biomarker in cancer prognosis are still unexplored.</p> Methods <p>In this study, we used integrative analysis of multi-omics data, including global gene expression, tumor immune infiltration, biological functions, molecular signatures, diagnostic value of biomarkers and responses to therapies in pan-cancer to evaluate the potential of GBP5 as a biomarker in cancer prognosis.</p> Results <p>Here, it is found that GBP5 is aberrantly expressed in the infiltrated immune cells in most cancer types. Furthermore, GBP5 not only responds to external cytokines, but also controls the expression of chemokines and immunomodulators. Consistently, GBP5 expression is positively associated with infiltration levels of immune cells in diverse cancer types. Moreover, GBP5 exhibits robust predictive power for response outcomes of immune checkpoint blockade (ICB) therapy compared to other 21 established biomarkers.</p> Conclusion <p>Altogether, our study strongly suggests that GBP5 is an onco-immunological biomarker with potential value for cancer prognosis and the efficacy prediction of ICB immunotherapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Aberrant expression of GBP5 in tumor-infiltrating immune cells as an onco-immunological biomarker in pan-cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月27日

查看全文
  • Rui Liu,
  • Jiaqian Gong,
  • Yuehang Zhang,
  • Qiuling Chen,
  • Ting Han,
  • Wenrui Li,
  • Hanrong Zhang,
  • Yichen Li

摘要

Background

Guanylate binding protein 5 (GBP5) belongs to an interferon (IFN)-inducible subfamily of guanosine triphosphatases (GTPases). GBP5 has been shown to promote NLRP3 inflammasome assembly, thereby playing a key role in innate immunity and inflammation. However, the role of GBP5 in the development of various cancers and its potential as a biomarker in cancer prognosis are still unexplored.

Methods

In this study, we used integrative analysis of multi-omics data, including global gene expression, tumor immune infiltration, biological functions, molecular signatures, diagnostic value of biomarkers and responses to therapies in pan-cancer to evaluate the potential of GBP5 as a biomarker in cancer prognosis.

Results

Here, it is found that GBP5 is aberrantly expressed in the infiltrated immune cells in most cancer types. Furthermore, GBP5 not only responds to external cytokines, but also controls the expression of chemokines and immunomodulators. Consistently, GBP5 expression is positively associated with infiltration levels of immune cells in diverse cancer types. Moreover, GBP5 exhibits robust predictive power for response outcomes of immune checkpoint blockade (ICB) therapy compared to other 21 established biomarkers.

Conclusion

Altogether, our study strongly suggests that GBP5 is an onco-immunological biomarker with potential value for cancer prognosis and the efficacy prediction of ICB immunotherapy.